P Vandenberghe

Summary

Affiliation: Katholieke Universiteit Leuven
Country: Belgium

Publications

  1. ncbi Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias
    P Vandenberghe
    The Center for Human Genetics, University Hospital Leuven, Leuven, Belgium
    Leukemia 18:734-42. 2004
  2. ncbi Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    K Spaepen
    Department of Nuclear Medicine, University Hospital Gasthuisberg and Catholic University of Leuven, Leuven, Belgium
    J Clin Oncol 19:414-9. 2001
  3. ncbi FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib
    E Lierman
    VIB Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium
    Leukemia 23:845-51. 2009
  4. ncbi A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification
    E Verburgh
    Department of Hematology, University Hospitals, University of Leuven, Leuven, Belgium
    Leukemia 21:668-77. 2007
  5. ncbi FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations
    I Wlodarska
    Center for Human Genetics, Katholieke Universiteit Leuven, Leuven, Belgium
    Leukemia 19:1299-305. 2005
  6. ncbi Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma
    K Spaepen
    Departments of Nuclear Medicine, University Hospital Gasthuisberg and Catholic University of Leuven, Leuven, Belgium
    Ann Oncol 13:1356-63. 2002
  7. ncbi Coexistence of light chain disease and chronic lymphocytic leukaemia, a complex karyotype with a rapid fatal outcome
    H Castryck
    Laboratory of Clinical Biology, Imelda Hospital, Bonheiden, Belgium
    Clin Lab Haematol 28:138-40. 2006
  8. ncbi CD34+ marrow progenitors from MDS patients with high levels of intramedullary apoptosis have reduced expression of alpha4beta1 and alpha5beta1 integrins
    M Delforge
    Department of Hematology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Leukemia 19:57-63. 2005
  9. ncbi Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas
    I Vanden Bempt
    Department of Pathology, University Hospital of K U Leuven, and Centre for Human Genetics, K U Leuven, Leuven, Belgium
    Histopathology 46:431-41. 2005
  10. ncbi Autoimmune haemolytic anaemia triggered by Bartonella henselae infection: a case report
    A Van Audenhove
    Department of Haematology, Internal Medicine, University Hospital Leuven, 49 Herestraat, B3000 Leuven, Belgium
    Br J Haematol 115:924-5. 2001

Collaborators

Detail Information

Publications26

  1. ncbi Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias
    P Vandenberghe
    The Center for Human Genetics, University Hospital Leuven, Leuven, Belgium
    Leukemia 18:734-42. 2004
    ..While RT-PCR and interphase FISH are equally valid diagnostic tools, the role of marrow biopsy in diagnosis and of RQ-PCR in disease and therapy monitoring needs further evaluation...
  2. ncbi Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    K Spaepen
    Department of Nuclear Medicine, University Hospital Gasthuisberg and Catholic University of Leuven, Leuven, Belgium
    J Clin Oncol 19:414-9. 2001
    ..In this study, we evaluated the value of PET in detecting residual disease and, hence, predicting relapse after first-line treatment in patients with non-Hodgkin's lymphoma (NHL)...
  3. ncbi FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib
    E Lierman
    VIB Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium
    Leukemia 23:845-51. 2009
    ..The identification of new PDGFR inhibitors will be required to overcome resistance by this D842V mutant...
  4. ncbi A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification
    E Verburgh
    Department of Hematology, University Hospitals, University of Leuven, Leuven, Belgium
    Leukemia 21:668-77. 2007
    ..This suggests that a standardized dysplasia scoring system, used in conjunction with cytopenia, could improve diagnostic and prognostic sub-categorization of MDS patients...
  5. ncbi FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations
    I Wlodarska
    Center for Human Genetics, Katholieke Universiteit Leuven, Leuven, Belgium
    Leukemia 19:1299-305. 2005
    ..However, over-representation of the FOXP1 locus found in one additional case of DLBCL may represent another potential mechanism underlying an increased expression of this gene...
  6. ncbi Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma
    K Spaepen
    Departments of Nuclear Medicine, University Hospital Gasthuisberg and Catholic University of Leuven, Leuven, Belgium
    Ann Oncol 13:1356-63. 2002
    ..This study was intended to assess the value of a midtreatment fluorine-18 fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) scan to predict clinical outcome in patients with aggressive NHL...
  7. ncbi Coexistence of light chain disease and chronic lymphocytic leukaemia, a complex karyotype with a rapid fatal outcome
    H Castryck
    Laboratory of Clinical Biology, Imelda Hospital, Bonheiden, Belgium
    Clin Lab Haematol 28:138-40. 2006
    ..We demonstrate the distinct clonal origin by cytogenetic data and immunoglobulin rearrangement studies. To our knowledge this is the first report of a light chain disease associated with CLL...
  8. ncbi CD34+ marrow progenitors from MDS patients with high levels of intramedullary apoptosis have reduced expression of alpha4beta1 and alpha5beta1 integrins
    M Delforge
    Department of Hematology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Leukemia 19:57-63. 2005
    ..Therefore, our observations suggest that downregulation of alpha4beta1 and alpha5beta1 integrins on CD34(+) progenitors could be a newly identified proapoptotic mechanism in MDS...
  9. ncbi Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas
    I Vanden Bempt
    Department of Pathology, University Hospital of K U Leuven, and Centre for Human Genetics, K U Leuven, Leuven, Belgium
    Histopathology 46:431-41. 2005
    ..To evaluate the HER-2/neu status at the mRNA and DNA level of breast carcinomas and to compare it with HER-2/neu receptor overexpression by immunohistochemistry (IHC)...
  10. ncbi Autoimmune haemolytic anaemia triggered by Bartonella henselae infection: a case report
    A Van Audenhove
    Department of Haematology, Internal Medicine, University Hospital Leuven, 49 Herestraat, B3000 Leuven, Belgium
    Br J Haematol 115:924-5. 2001
    ..Concomitant serum titres of B. henselae antibodies were indicative of a recent infection. The case report suggests that B. henselae infection can trigger secondary autoimmune haemolytic anaemia...
  11. ncbi Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia
    C Graux
    Department of Human Genetics, University of Leuven, Leuven, Belgium
    Nat Genet 36:1084-9. 2004
    ..NUP214-ABL1 expression defines a new subgroup of individuals with T-ALL who could benefit from treatment with imatinib...
  12. ncbi Circulating myeloid and lymphoid precursor dendritic cells are clonally involved in myelodysplastic syndromes
    L Ma
    Laboratory for Experimental Hematology, University of Leuven, Leuven, Belgium
    Leukemia 18:1451-6. 2004
    ..These data therefore strongly suggest that myeloid and lymphoid pDC share a common precursor. Whether reduced peripheral blood counts of pDC contribute to the immunological abnormalities observed in MDS remains to be investigated...
  13. ncbi Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
    K Spaepen
    Department of Nuclear Medicine, University Hospital Gasthuisberg and Catholic University of Leuven, Leuven, Belgium
    Br J Haematol 115:272-8. 2001
    ..Two-year actuarial PFS rate for negative patients was 91% compared with 0% for positive patients. We concluded that [(18)F]-FDG-PET has an important prognostic role in the post-treatment evaluation of HD patients...
  14. ncbi [A man with FIP1L1/PDGFRA-positive chronic eosinophilic leukemia]
    O C Leeksma
    Onze Lieve Vrouwe Gasthuis, Oosterpark, HM Amsterdam
    Ned Tijdschr Geneeskd 150:1936-43. 2006
    ..After 1 year of follow up, the patient was in complete haematological and molecular remission for chronic eosinophilic leukaemia. The cardiac mass remained unchanged, but caused no haemodynamic problems...
  15. ncbi Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine
    E Van den Neste
    Department of Hematology Hematological Biology, Cliniques Universitaires UCL Saint Luc, Brussels, Belgium
    Leukemia 21:1715-22. 2007
    ..IgV(H) mutational status was independently associated with risk of failure and TFS, but not OS. In B-CLL patients treated with CdA, translocations are strong predictors of outcome...
  16. ncbi FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells
    B Crescenzi
    Hematology and Bone Marrow Transplantation Unit, University of Perugia, Perugia, Italy
    Leukemia 21:397-402. 2007
    ..This study provided evidence for marked differences in the leukemic masses which are targeted by imatinib in CEL or CML, as harboring FIP1L1-PDGFRA or BCR-ABL1...
  17. ncbi Genetic lesions and the malignant phenotype of haematological cancers
    P Vandenberghe
    Centrum voor Menselijke Erfelijkheid, Universitaire Ziekenhuizen Leuven en KULeuven, Herestraat 49, B 3000 Leuven
    Verh K Acad Geneeskd Belg 69:291-313. 2007
    ..In this paper, we review our recent contributions to this cancer paradigm in malignant or premalignant haematological conditions...
  18. ncbi Interstitial del(14)(q) involving IGH: a novel recurrent aberration in B-NHL
    H Pospisilova
    Leukemia 21:2079-83. 2007
  19. ncbi Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation
    P Vandenberghe
    Leukemia 17:458-60. 2003
  20. ncbi Transition from EML1-ABL1 to NUP214-ABL1 positivity in a patient with acute T-lymphoblastic leukemia
    K De Keersmaecker
    Leukemia 20:2202-4. 2006
  21. ncbi A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias
    F Speleman
    Centre for Medical Genetics, Ghent University Hospital, Ghent, Belgium
    Leukemia 19:358-66. 2005
    ..Finally, our observation also supports the previous suggested role of HOXA10 and HOXA11 in normal thymocyte development...
  22. ncbi Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast
    C Graux
    Department of Hematology, Cliniques Universitaires St Luc, Catholic University of Louvain, Brussels, Belgium
    Leukemia 20:1496-510. 2006
    ..They also open perspectives for targeted therapies...
  23. ncbi Quantification of CBFB-MYH11 fusion gene levels in paired peripheral blood and bone marrow samples by real-time PCR
    N Boeckx
    Leukemia 19:1988-90. 2005
  24. ncbi Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances
    S Franke
    Center for Human Genetics, The Department of Pathology, the Laboratory of Experimental Hematology, Catholic University of Leuven, Belgium
    Blood 97:1845-53. 2001
    ..In conclusion, the data show a consistent occurrence of genomic alterations in LPHD and highlight genomic regions that might be relevant for development and/or progression of this lymphoma entity...
  25. ncbi Identification of e19a2 BCR-ABL fusions (mu-BCR breakpoints) at the DNA level by ligation-mediated PCR
    N Boeckx
    Leukemia 19:1292-5. 2005
  26. ncbi Deletion of the inositide-specific phospholipase c beta1 gene is a rare event in myelodysplastic syndrome and thus of limited value to predict leukemic progression
    E Verburgh
    Leukemia 19:2011-3. 2005